Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jelectrocard.2020.10.015 http://scihub22266oqcxt.onion/10.1016/j.jelectrocard.2020.10.015 33181454!7647409!33181454     free     free     free       J+Electrocardiol 2020 ; 63 (?): 115-119 Nephropedia Template TP {{tp|p=33181454|t=2020. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019 |pdf=|usr=}}{{33181454}} gab.com Text The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019 JO: J Electrocardiol http://www.kidney.de/pget.php?&tw=1&pmid=33181454 #FOAvip BACKGROUND: The effect of favipiravir on the QTc interval during the treatment of Coronavirus Disease 2019 (COVID-19) patients is unclear. Thus, the current study objective was to evaluate any change in the QTc interval in patients who were hospitalized due to COVID-19 receiving favipiravir treatment. METHOD: Patients hospitalized with COVID-19 were assessed in this single-center retrospective study. 189 patients, whose diagnosis was confirmed using real-time PCR, were included in the study. The patients were divided into three groups: those using hydroxychloroquine (Group 1, n?=?66), hydroxychloroquine plus favipiravir (Group 2, n?=?66), and favipiravir only (Group 3, n?=?57). The QTc interval was measured before treatment (QTc-B) and 48?h after (i.e., the median) starting treatment (QTc-AT). RESULTS: The median age was 53 (39-66 IQR) and 97 (51%) of patients were female. The median QTc(Bazett)-change was 7?ms (p?=?0.028) and 12?ms (p?<?0.001) and in Group 1 and 2, respectively. In Group 3, the median QTc(Bazett)-change was observed as -3?ms and was not statistically significant (p?=?0.247). In multivariable analysis, while there was a significant relationship between QTc-AT(Bazett) and hydroxychloroquine (beta coefficient?=?2687, 95%CI 2599-16,976, p?=?0,008), there was no significant relationship with favipiravir (beta coefficient?=?0,180, 95% CI -6435-7724, p?=?0,858). Similarly, there was a significant relationship between the QTc-AT interval calculated using the Fredericia formula and hydroxychloroquine (beta coefficient?=?2120, 95% CI 0,514-14,398, p?=?0,035), but not with favipiravir (beta coefficient?=?0,111, 95% CI -6450- 7221, p?=?0,911). CONCLUSION: In the ECG recordings received in the following days after the treatment was started in COVID-19 patients, there was a significant prolongation in the QTc interval with hydroxychloroquine, but there was no significant change with favipiravir. Twit Text FOAVip The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019 ????J Electrocardiol http://www.kidney.de/pget.php?&tw=1&pmid=33181454 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33181454 #FOAvip English Wikipedia <ref>{{Cite pmid|33181454}}</ref> The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019 #MMPMID33181454 Cap M; Bilge O; Isik F; Burak C; Karagoz A; Inci U; Akyuz A; Aslan B; Altintas B; Altindag R; Kaya I; Adiyaman MS; Suleymanoglu M; Kaya S; Baysal E J Electrocardiol 2020[Nov]; 63 (?): 115-119 PMID33181454show ga BACKGROUND: The effect of favipiravir on the QTc interval during the treatment of Coronavirus Disease 2019 (COVID-19) patients is unclear. Thus, the current study objective was to evaluate any change in the QTc interval in patients who were hospitalized due to COVID-19 receiving favipiravir treatment. METHOD: Patients hospitalized with COVID-19 were assessed in this single-center retrospective study. 189 patients, whose diagnosis was confirmed using real-time PCR, were included in the study. The patients were divided into three groups: those using hydroxychloroquine (Group 1, n?=?66), hydroxychloroquine plus favipiravir (Group 2, n?=?66), and favipiravir only (Group 3, n?=?57). The QTc interval was measured before treatment (QTc-B) and 48?h after (i.e., the median) starting treatment (QTc-AT). RESULTS: The median age was 53 (39-66 IQR) and 97 (51%) of patients were female. The median QTc(Bazett)-change was 7?ms (p?=?0.028) and 12?ms (p? |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Aged[MESH] |Amides/*therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19 Testing[MESH] |Electrocardiography[MESH] |Female[MESH] |Hospitalization[MESH] |Humans[MESH] |Hydroxychloroquine/*therapeutic use[MESH] |Long QT Syndrome/*chemically induced[MESH] |Male[MESH] |Middle Aged[MESH] |Pyrazines/*therapeutic use[MESH] |Retrospective Studies[MESH]The effect of favipiravir on QTc interval in patients hospitalized wit(epmc).pdf DeepDyve Pubget Overpricing